Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36520037.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3229.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors have revolutionized the treatment of multiple solid malignancies, but their role in the treatment of neuroendocrine neoplasms (NEN) is unclear. The accompanying article reports on a study combining the programmed cell death (PD-1) inhibitor nivolumab with the alkylating agent temozolomide in patients with advanced NENs. See related article by Owen et al., p. 731.
Medical subject headings
- Nivolumab
- Neuroendocrine Tumors